← Oncology Approval Tracker

FDA DECISION ·

Cyramza + erlotinib

ramucirumab + erlotinib · Eli Lilly

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment for metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R substitution.

LAMPGEN ANALYSIS

Why it matters

Added VEGFR2 inhibition to an EGFR-directed regimen for two common sensitizing alterations.

What research teams should watch

Match the exact EGFR variant and plan blood pressure and proteinuria monitoring.

PRIMARY RECORDS

Sources